Liraglutide Treatment to Patients With Severe Renal Insufficiency
This study has been completed.
Novo Nordisk A/S
The GCP unit at Copenhagen University Hospital
Information provided by (Responsible Party):
Bo Feldt-Rasmussen, Rigshospitalet, Denmark
First received: July 11, 2011
Last updated: October 8, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||October 2013|
|Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Idorn T, Knop FK, Jørgensen MB, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B. Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016 Feb;39(2):206-13. doi: 10.2337/dc15-1025. Epub 2015 Aug 17.
Idorn T, Knop FK, Jørgensen M, Jensen T, Resuli M, Hansen PM, Christensen KB, Holst JJ, Hornum M, Feldt-Rasmussen B. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open. 2013 Apr 26;3(4). pii: e002764. doi: 10.1136/bmjopen-2013-002764. Print 2013.